Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Oxford Nanopore announcement sets sequencing sector abuzz

Nature Biotechnology volume 30, pages 295–296 (2012)Cite this article

Subjects

A steady stream of money is now flowing into efforts to apply whole-genome and exome sequencing toward the development of patient-specific treatment strategies, with numerous medical schools and hospitals forming centers focused on personalized medicine. This past winter the US National Human Genome Research Institute issued more than $10 million in funding for Clinical Sequencing Exploratory Research Projects to investigators at six different institutions. “The rate at which this is actually happening is vastly exceeding our expectations,” says Richard Gibbs, director of the Human Genome Sequencing Center at Baylor University in Waco, Texas.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Philadelphia, Pennsylvania

    Michael Eisenstein

Authors
  1. Michael Eisenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eisenstein, M. Oxford Nanopore announcement sets sequencing sector abuzz. Nat Biotechnol 30, 295–296 (2012). https://doi.org/10.1038/nbt0412-295

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0412-295

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research